DBV Technologies Announces Topline Financial Results for First Nine Months 2014

Bagneux, France, October 14th, 2014 - DBV Technologies, (Euronext: DBV – ISIN: FR0010417345), announced today its topline financial results, as well as its cash and cash equivalents, for first nine months 2014.

Topline Financial Results for first nine months 2014
For the first nine months 2014, total income reached €3,914,707, up from €2,535,963 for the same period in 2013. This increase primarily results from an increase in Research Tax Credit amounting to €3,562,796 over the period, compared to €2,271,494 a year earlier. This progression stems from the R&D activities conducted by DBV, both on the pre-clinical research and clinical development fronts. Sales of Diallertest® amounted to €210,759 in the first nine months 2014 compared with €73,840 a year earlier, due to a stocking effect at the Company’s commercial partner.

Cash and cash equivalents at 30 September 2014
As of 30 September 2014, DBV’s cash and cash equivalents amounted to €21.3 million, as compared with €29.1 million as of June 30, 2014 and €39.4 million as of December 31, 2013. A Research Tax Credit for 2013 in the amount of €3.3 million has not yet been received but is expected in the fourth quarter of 2014.

About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

Forward Looking Statements
This press release contains forward-looking statements, including statements about the safety and efficacy of DBV Technologies’ product. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise.
DBV Technologies Contacts

David Schilansky
Chief Financial Officer
Tel.: +33(0)1 55 42 78 78
david.schilansky@dbv-technologies.com

Susanna Mesa
VP Finance, US Investor Relations & Strategy
Tel.: +1 917-346-3447
susanna.mesa@dbv-technologies.com

Nathalie Donne
Director, Corporate Communication & Business Development
Tel.: +33(0)1 55 42 78 78
nathalie.donne@dbv-technologies.com

DBV IR and Media Contacts

The Trout Group
U.S. Investor Relations
Todd James
Tel.: +1 646-378-2926
tjames@troutgroup.com

Rooney & Associates
Media Relations
Marion Janic
Tel.: +1-212-223-4017
mjanic@rooneyco.com